Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00371345 · ClinicalTrials.gov registry record · Phase 2
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00371345 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 92 participants.
The verdict
NCT00371345, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer
Interventions
- DRUG Dasatinib
- DRUG Dasatinib 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00371345
The ClinicalTrials.gov registry entry for NCT00371345 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT00371345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00371345 about?
NCT00371345 is a clinical study titled "Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer". This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer
What is the current status of trial NCT00371345?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2006-12. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00371345?
The interventions under investigation include: Dasatinib (DRUG), Dasatinib 100 mg (DRUG).
Who is sponsoring clinical trial NCT00371345?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.